The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of treatment-free remission in chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitor therapy.
 
Mehmet Uyanik
No Relationships to Disclose
 
Fadi Haddad
Consulting or Advisory Role - SOBI
 
Koji Sasaki
Honoraria - Amgen; Chugai Pharma; Otsuka
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Research Funding - Novartis
Travel, Accommodations, Expenses - Amgen; Otsuka
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
Jayastu Senapati
No Relationships to Disclose
 
Nicholas Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); KisoJi Biotechnology (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); Medisix Therapeutics (Inst); MingSight (Inst); Newave Pharmaceutical (Inst); NovalGen (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Sana Biotechnology (Inst); SERVIER (Inst); Takeda (Inst); TransThera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Lucia Masarova
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Cogent Biosciences; Pharmaessentia
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - MorphoSys
 
Courtney Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER
 
Tapan Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; Sellas Life Sciences; SERVIER
Research Funding - Abcuro; Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; DAAN Biotherapeutics; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst); Sellas Life Sciences
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma; Autolus; Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; TargetRX; Terns Pharmaceuticals
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Terns Pharmaceuticals; TGRX
Travel, Accommodations, Expenses - Aptitude Health; Autolus; Daiichi Sankyo Nordics; HMP Education; MD Education; Nucleus Global; ONVIV; Pfizer
 
Hagop Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; KAHR Medical; Novartis; Pfizer; Shenzhen Target Rx
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)